Moreover, high TRMT112 expression was particularly linked to poorer immune-related prognosis in HPV-negative HNSCC patients, suggesting its potential role in modulating tumor–immune interactions (P = 0.01; Fig. 3F). Here, TRMT112 is linked to head and neck squamous cell carcinoma.